Circular No. 19/2001-Cus.
23rd March, 2001.
F.NO.605/47/2001-DBK
Government
of India
Ministry
of Finance
Department
of Revenue
Sub: Export of sub-standard drugs by various
companies and claiming DEPB /Drawback benefits thereon.
DRI has issues an alert Circular No. 12/2001 from F.No. 50D/9/2001-C1 dated
09.02.2001 on the above subject whereas it appears that certain lesser known
companies are attempting to export sub-standard formulations, which do not
conform to the composition declared on the containers/labels, and may be of
little therapeutical value and may not conform to pharmacoepea; these drugs are
attempted to be exported under various export promotion schemes.
- In such cases, it appears that the actual
composition of drugs exported is different from the composition given on the
containers/labels, and thus would constitute mis-declaration. Such cases
would fall under the category of mis-declaration under various provisions of
Customs Act, which would be attracted in such cases. In view thereof, apart
from necessary action under the Customs Act such exports would not be
eligible to the benefits under various export promotion schemes which are
otherwise available for export of certain standard formulations assuming
certain percentages of active ingredients imparting therapeutical properties
etc.
- Contents of this Circular may be brought to
the notice of the concerned officers and a watch be kept to ensure that
attempt is not made to get away with unwarranted export benefits by
misdeclaring nature & composition of Drugs / formulations.